⚡Cytonics is disrupting the traditional biotech funding model to accelerate research and development for the net benefit of humanity.
The success of securing funding in biotech is a massively challenging task that is necessary for transforming innovative research into life-changing therapies. Cytonics is at the forefront, utilizing both traditional funding mechanisms and pioneering methods like equity crowdfunding. Here’s how each stage of funding contributes to our progress and offers strategic benefits to investors.
🌱 Seed and Early Funding Stages
Early investments have propelled our initial research into the potential of A2M-based therapies. These foundational funds were crucial for achieving our proof-of-concept and setting the stage for more substantial funding rounds. We secured Seed stage capital from 150 accredited investors, many of whom are physicians and patients that have implemented and benefitted from our Autologous Protease Inhibitor Concentrate (APIC) therapy for osteoarthritis. These early investors have remained steadfast and loyal – reinvesting in each funding round and touting the efficacy of Cytonics’ therapies.
👨⚕️Here’s what our physician investors have to say about our technology.
💼 Series A and B Funding
During traditional Series A and B funding rounds, venture capital firms typically focus on scaling operations and advancing clinical trials, assessing the scalability of the technology, team capabilities, and preliminary data. However, the post-COVID market saw a decrease in VC funding as risk aversion grew, pushing many biotechs towards closure. In response, Cytonics pivoted to equity crowdfunding, a revolutionary approach that opens up investment in cutting-edge biotechnology to everyone, not just institutional investors. This strategy not only diversified our funding base but also transformed our investors into passionate advocates for our therapies, enhancing our consumer-focused product development with valuable community feedback. By democratizing investment opportunities, equity crowdfunding allows everyday investors to participate in potentially lucrative returns, taking power away from the Venture Capitalists and empowering Cytonics to navigate funding challenges and position itself for robust future growth.
🪙 Invest Like A Venture Capitalist
To date, we have raised over $15M from four different Reg CF and Reg A+ raises. This consistent success is a testament to our ability to turn your dollars into real value by advancing our drug development program for osteoarthritis into clinical trials.
🎯 Late-Stage Funding
As Cytonics progresses through clinical trials, late-stage funding may include larger institutional investors and strategic partnerships, preparing us for a public offering or acquisition. The success of securing late-stage funding is predicated on successful Phase 2 and/or 3 clinical trials, which de-risks the drug development and significantly increases the probability of bringing a drug to market. At this stage, investors and management turn their attention towards positioning the drug asset(s) for commercialization, giving consideration to manufacturing, marketing, and scaling operations to meet global demand. Cytonics’ plan is to complete Phase 1 and 2 clinical trials (funded by equity crowdfunding!), then aligning with a strategic partner to fund Phase 3 or sell our entire intellectual property portfolio to an acquirer.
🌿 So You Want To Be A Biotech Investor?
🧩 Last Piece Of The Puzzle
The final stage in the lifecycle of a biotech is the shareholder “exit. Biotech exits come in two flavors: acquisition or an Initial Public Offering (IPO). Both of these options may offer substantial returns to early investors. Cytonics’ goal is to advance our lead drug candidate for osteoarthritis, “CYT-108,” through Phase 2 clinical trials and then decide on exit strategy. The timing and nature of the exit will depend on market conditions and the success of our clinical programs.
🪙 Why Invest in Cytonics?
Investing in Cytonics through equity crowdfunding allows you to participate in a potentially disruptive biotech development at an early stage. With each clinical milestone achieved, we anticipate an increase in valuation, enhancing the potential for returns at exit.
To take part in our journey and help bring new solutions to millions suffering from osteoarthritis. Your investment is not just a financial play. It is the opportunity to make a significant contribution to the betterment of human health and well-being.
Ready to become a shareholder? Visit invest.cytonics.com.
This communication may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.
Leave a Reply